Free Trial
NASDAQ:QNTM

Quantum Biopharma (QNTM) Stock Price, News & Analysis

Quantum Biopharma logo
$3.84 -0.17 (-4.24%)
As of 01/6/2025 03:59 PM Eastern

About Quantum Biopharma Stock (NASDAQ:QNTM)

Key Stats

Today's Range
$3.84
$4.09
50-Day Range
$3.00
$5.63
52-Week Range
$2.70
$70.85
Volume
77,944 shs
Average Volume
69,981 shs
Market Capitalization
$7.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.

Receive QNTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quantum Biopharma and its competitors with MarketBeat's FREE daily newsletter.

QNTM Stock News Headlines

[EXPOSED] Little-known Bitcoin “Loophole”
I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…
Quantum BioPharma Advances Lucid-21-302 Clinical Trial
Quantum BioPharma Launches $5 Million Private Placement
See More Headlines

QNTM Stock Analysis - Frequently Asked Questions

Quantum Biopharma's stock was trading at $3.68 at the start of the year. Since then, QNTM shares have increased by 4.3% and is now trading at $3.84.
View the best growth stocks for 2025 here
.

Shares of QNTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Quantum Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC).

Company Calendar

Today
1/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:QNTM
Previous Symbol
NASDAQ:QNTM
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-17,900,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$21.29 per share

Miscellaneous

Free Float
1,755,000
Market Cap
$7.37 million
Optionable
N/A
Beta
0.60
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:QNTM) was last updated on 1/7/2025 by MarketBeat.com Staff
From Our Partners